Page 2 - Modified Intent News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Modified Intent. Real-time updates on events, politics, business and more.

Acurx Pharmaceuticals Stock Is Plummeting After Biotech Publishes Phase 2 Results - Acurx Pharmaceuticals (NASDAQ:ACXP)

November 2, 2023

Acurx Pharmaceuticals Inc&nbsp;(NASDAQ: ACXP) shares are trading lower after the company&nbsp;

David Luci Data Monitoring Committee Acurx Pharmaceuticals Inc Pharmaceuticals Inc Independent Data Monitoring Committee Clinical Cure

Source: benzinga.com

Acurx Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. difficile Infection

November 2, 2023

In a total of 26 ibezapolstat-treated patients in Phases 2a and 2b, the Clinical Cure rate is 96% Meets protocol primary objective of assessing the primary...

United States Davidp Luci Robertj Deluccia Kevin Garey Stuart Johnson Peggy Lillis Foundation

Source: prnewswire.com

Pliant Therapeutics Announces Positive Data from the

January 22, 2023

Bexotegrast demonstrated statistically significant increase in FVC at 4, 8 and 12 weeks of treatment, outperforming lower dose groups No...

Group Demonstrated Strong Treatment Pliant Therapeutics Inc Bexotegrast Clinical Development Next Quantitative Lung Fibrosis Well Tolerated Serious Adverse

Source: globenewswire.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Page 2 - Modified Intent News Today

Acurx Pharmaceuticals Stock Is Plummeting After Biotech Publishes Phase 2 Results - Acurx Pharmaceuticals (NASDAQ:ACXP)

Acurx Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. difficile Infection

Pliant Therapeutics Announces Positive Data from the

Explore More Categories